1 / 6

Continuous Glucose Monitoring Systems Market Rising Vastly Up with Massive CAGR Over the Coming Years

Continuous Glucose Monitoring Systems Market was valued at $894 million in 2016, and is projected to reach $4,921 million by 2024, registering a CAGR of 22.9% from 2018 to 2024.

newmarketindustry
Download Presentation

Continuous Glucose Monitoring Systems Market Rising Vastly Up with Massive CAGR Over the Coming Years

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Continuous Glucose Monitoring Systems Market

  2. Benefits of CGMS over POC glucometers, rise in incidence of diabetes cases and high-end technological advancements in medical sector have amplified the growth of the market in more than one way. On the other hand, certain adverse effects of the system and several strict guidelines by the Government have happened to curb the growth to some extent. However, high adoption rate of CGMS in home healthcare, increase in product awareness and rise in undiagnosed patient population have created multiple opportunities in the segment. The Global Continuous Glucose Monitoring Systems Market was estimated at $758 million in 2017 and is anticipated to hit $4,921 million by 2024, airing a CAGR of 22.9% from 2016-2024. Get Sample Report

  3. Benefits of CGMS over POC glucometers, rise in incidence of diabetes cases and high-end technological advancements in medical sector have amplified the growth of the market in more than one way. On the other hand, certain adverse effects of the system and several strict guidelines by the Government have happened to curb the growth to some extent. However, high adoption rate of CGMS in home healthcare, increase in product awareness and rise in undiagnosed patient population have created multiple opportunities in the segment.

  4. The report offers a thorough analysis of market dynamics, top investment pockets, market definition & scope, key market trends and market size. Based on components, the sensors segment is remains to be the largest sector, airing a CAGR of 22.9% during the forecast period. The expected technological advances has rocketed the growth and made the segment hold major market share. By end user, diagnostic centers/clinics dominate the global market, garnering a CAGR of 22.1% throughout the forecast period. Cutting-edge CGMS programs in diagnostics clinics have spurred the growth. Simultaneously, home health care has been cited as the fastest growing market, registering a CAGR of 30.9% from 2016-2024. This is due to the fact that continuous glucose monitoring systems are easier to use and are less painful.

  5. Key Findings of the Continuous Glucose Monitoring Systems (CGMS) Market: • The sensors segment contributed for nearly two-third share of the global continuous glucose monitoring systems market in 2016. • The integrated insulin pumps segment is projected to grow at a significant CAGR of 17.3% from 2018 to 2023. • The ICUs segment is projected to grow at a significant CAGR of 22.3% during the forecast period. • Germany and France are the major shareholders, which collectively accounted for more than one-fourth share of the European continuous glucose monitoring systems market in 2016. • Japan is the major shareholder, accounting for more than one-fourth share of the Asia-Pacific continuous glucose monitoring systems market in 2016.

  6. Industry Key Players The report offers quite a few key market players including Dexcom, Inc., Abbott Laboratories, Echo Therapeutics, Inc., Insulet Corporation, F. Hoffmann-La Roche Ltd., Senseonics Holdings, Menarini Diagnostics, GlySens Incorporated, Johnson & Johnson and Medtronic plc, Inc

More Related